For example, while immunotherapy (e.g., ICIs such as anti-PD-1 antibodies) has transformed the treatment landscape for many cancer patients (e.g., lung, melanoma), for PDAC patients, <2% show improved outcomes. Here, PDCD1 is linked to cancer.